2 former Apple Tree investors roll toward new biotech-focused fund launching with $310M

Preview

来源: FierceBiotech

Scion co-founders Sam Hall, Ph.D., and Aaron Kantoff were colleagues for six years at Apple Tree Partners until 2019.

Two former Apple Tree investors have set off on their own path, blossoming a new biotech-focused incubator with an inaugural fund of $310 million.

Scion Life Sciences officially hit the stage Tuesday morning, led by Sam Hall, Ph.D., and Aaron Kantoff, who overlapped at VC firm Apple Tree Partners for six years until 2019. Kantoff, co-founder of Bristol Myers Squibb-bought RayzeBio, also spent some time as a venture partner at European investment firm Medicxi before starting Scion.

Scion’s core mission is not too different from many other biotech investors, with an emphasis on directing capital to scientists and research that have a high probability of success and could result in paradigm-shifting medicines. To accomplish that, Scion and its founders are laying out a concise road map that starts with incubating early science focused on biologics and large-molecule development.

The firm’s in-house R&D capabilities, dubbed Scion Innovations, will be used as a proving ground for scientists and entrepreneurs looking to establish their first programs. Scion said in its announcement that “only programs with exceptional potential mature into full-scale portfolio company investments.”

“We really want to be ruthless early in the incubation of the projects and companies we build,” Hall told Fierce Biotech in an interview alongside Kantoff. “We want to address head-on all of the key existential risks that we see that … confront the project and company build,” Hall added.

The reason the fund is prioritizing large-molecule and biologics development is that this space spans some of the most mature science, according to the founders. Scion has “four promising company formation efforts underway,” as noted in a press release, which Kantoff elaborated span bispecific antibodies, conjugates, and gene and cell therapy. None of the potential companies are working on cancer treatments.

Kantoff expects at least one of the four companies currently being incubated to launch before the end of the year, with another possibly on the cards as well. The effort to grow those biotechs so far has happened in parallel with fundraising efforts, which went as well as Kantoff and Hall could have imagined. They set out to raise $250 million with a hard cap of $300 million, but, thanks to “the tremendous amount of interest and momentum,” according to Kantoff, the investor syndicate agreed to raise the cap to $310 million.

The firm is affiliated with healthcare private equity company Petrichor, although Scion’s founders insist the two will operate separately. Hall described the two entities as “separate businesses with partners in common,” with a relationship principally focused on shares administrative functions. Tadd Wessel, Petrichor’s managing director, is a co-founder and managing director of Scion.

“I and the entire Petrichor team are delighted to partner with them in building Scion,” Wessel said in Scion's release.

Editor's note: This story was updated to correct that Petrichor and Scion do not have a tax partnership. The author misheard "Tadd's partnership" in the interview.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。